Feikai Materials: In 2021, the downstream customers of the company’s pharmaceutical intermediate products will continue to increase, and the annual sales will increase significantly_ Securities Times Network

Securities Times e Company News, Feikai Materials (300398) said on the interactive platform today that there is currently no third-party authoritative statistical information on the company’s market share of bromoacetonitrile, and the company cannot judge whether it is used in Pfizer and other new coronavirus prevention and treatment special drugs. In 2021, the downstream customers of the company’s pharmaceutical intermediate products will continue to increase, and the annual sales volume will increase significantly. It is reported that some customers of the company’s pharmaceutical intermediate products include upstream API factories of Huahai, Pfizer, Hisun and other pharmaceutical companies, and their use belongs to the customers’ own business information.